Orchid Pharma, erstwhile Orchid Chemicals and Pharmaceuticals Ltd, on Tuesday informed the exchanges that it has received abbreviated new drug application (ANDA) approval from the US FDA for Risedronate Sodium tablets USP, 30 mg and 35 mg. The drug (bisphosphonate) is used for the treatment and prevention of osteoporosis, the statement added. Shareholders of the loss-making pharma firm will closely monitor further developments.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.